- home
- About Us
- Our Mission & Value
- Our Story
- Leadership
- Investors
Our Story
-
FOUNDING YEAR
2015
-
TEAM MEMBERS
70+ As of May
-
FUNDING STAGE
Series B (2020)
Series A (2018)
-
THERAPEUTIC AREAS
Inflammatory diseases
Oncology
CNS diseases
LEADERSHIP
- Chulhee Choi, MD, PhD
- Founder and CEO, Chairman
- Taejin Ham, RPh, MBA
- President and CEO
Platform Technologies
- EXPLOR®
- Exosome engineering for protein loading
- Exo-Target®
- Exosome surface engineering for targeting
- Pure-Exo®
- Robust and scalable exosome manufacturing
LOCATIONS
-
- Headquarter
- 40-20 Techno 6-ro, Yuseong-gu, Daejeon, 34014, Republic of Korea
-
- Seoul Office
- 6F B-dong, 24-2 Samseong-ro 100-gil, Gangnam-gu, Seoul, 06167, Republic of Korea
-
- US Office
- ILIAS Therapeutics, Inc. 7880 Wren Avenue, Suite D138, Gilroy, CA 9520, USA
Our History
2023
-
Aug.
- Completed dosing of ILB-202 in phase1 clinical trial in Australia
-
Jun.
- Designation as the Excellent Corporation R&D Center(ECRC) by Ministry of Science and ICT
-
May.
- Completed the first dosing of ILB-202 in clinical trial in Australia
-
Feb.
- Granted patent for Exo-Target® in Canada, Japan
- Published 'ILB-202 efficacy in ALD’ in Pharmaceutics
- Published ‘ILB-202 efficacy in CPIP’ in Pharmaceutics
2022
-
Oct.
- Started offering 'EV2aluation service'
-
Jun.
- Selected as the Winner of the National Research Project issued by Korea Drug Development Fund (KDDF)
-
Jun.
- Research collaboration with JW Pharmaceutical to develop an exosome-based small molecular anti-cancer treatment
-
May.
- MOU with HK inno.N for joint research to develop new biomedicine candidates
-
Apr.
- Approved a phase 1 clinical trial of ILB-202 by the Human Research Ethics Committee (HREC) in Australia
2021
-
Jun.
- Granted patent for EXPLOR® in China, Japan
-
May.
- Published ‘ILB-202 preclinical efficacy in IRI-AKI model’ in Kidney International
-
Jan.
- Published ‘ILB-202 preclinical efficacy in preterm birth model’ in Science Advances
2020
-
Nov.
- Won the Cytiva Korea CEO Award at the 2020 BioChallenge
-
Sep.
- Raised $20M in a series B funding
-
Jul.
- Granted a key exosome enginerring patent EXPLOR® in US
-
Apr.
- Published the preclinical data of anti-inflamatory protein-loaded exosomes (ILB-202) in Science Advances
-
Apr.
- Won the Grand prize at the 2020 Korea Industry & Best Enterprise Award
2019
-
Nov.
- Received the Ministerial Citation by the Korean Ministry of Health and Welfare
-
Mar.
- Received NIH R21 grant for exosome-based research
-
Jan.
- Established ILIAS Therapeutics, Inc. in New York, USA.
2018
-
Jun.
- Raised over $17M in a series A funding
2017
-
May.
- Granted a key exosome enginerring patent EXPLOR® in Korea
2016
-
Jul.
- Published EXPLOR® technology in Nature Communications
2015
-
Nov.
- Foundation
Republic of Korea
USA
